These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 9643779)

  • 1. New-variant Creutzfeldt-Jakob disease and treatment of haemophilia. Executive Committee UK Haemophilia Directors' Organisation.
    Ludlam CA
    Lancet; 1998 Apr; 351(9111):1289-90. PubMed ID: 9643779
    [No Abstract]   [Full Text] [Related]  

  • 2. New-variant Creutzfeldt-Jakob disease and treatment of haemophilia. Executive Committee of the UKHCDO. United Kingdom Haemophilia Centre Directors' Organisation.
    Ludlam CA
    Lancet; 1997 Dec; 350(9092):1704. PubMed ID: 9400534
    [No Abstract]   [Full Text] [Related]  

  • 3. New-variant Creutzfeldt-Jakob disease and treatment of haemophilia.
    Baxter T; Black D; Birks D
    Lancet; 1998 Feb; 351(9102):600-1. PubMed ID: 9492811
    [No Abstract]   [Full Text] [Related]  

  • 4. Haemophilia patient had variant CJD agent in spleen.
    Eaton L
    BMJ; 2009 Feb; 338():b705. PubMed ID: 19224963
    [No Abstract]   [Full Text] [Related]  

  • 5. Recommendations for the treatment of factor VIII inhibitors: from the UK Haemophilia Centre Directors' Organisation Inhibitor Working Party.
    Hay CR; Colvin BT; Ludlam CA; Hill FG; Preston FE
    Blood Coagul Fibrinolysis; 1996 Mar; 7(2):134-8. PubMed ID: 8735802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical implications of emerging pathogens in haemophilia: the variant Creutzfeldt-Jakob disease experience.
    Dolan G
    Haemophilia; 2006 Mar; 12 Suppl 1():16-20; discussion 26-8. PubMed ID: 16445813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Who should receive recombinant factor VIII?
    Giangrande PL
    Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S25-7. PubMed ID: 9351533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factor VIII and transmissible spongiform encephalopathy: the case for safety.
    Cervenakova L; Brown P; Hammond DJ; Lee CA; Saenko EL
    Haemophilia; 2002 Mar; 8(2):63-75. PubMed ID: 11952840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma-derived versus recombinant Factor VIII concentrates for the treatment of haemophilia A: recombinant is better.
    Franchini M
    Blood Transfus; 2010 Oct; 8(4):292-6. PubMed ID: 20967172
    [No Abstract]   [Full Text] [Related]  

  • 10. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
    CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. UK accused over risk of CJD in plasma...and latest BSE beef ban 'comes too late'.
    Butler D
    Nature; 1997 Dec; 390(6660):541. PubMed ID: 9403673
    [No Abstract]   [Full Text] [Related]  

  • 12. Creutzfeldt-Jakob disease and haemophilia: assessment of risk.
    Evatt B
    Haemophilia; 2000 Jul; 6 Suppl 1():94-9. PubMed ID: 10982274
    [No Abstract]   [Full Text] [Related]  

  • 13. The current status of recombinant human factor VIII.
    Aronson DL
    Semin Hematol; 1991 Apr; 28(2 Suppl 1):55-6. PubMed ID: 1908131
    [No Abstract]   [Full Text] [Related]  

  • 14. Plasma-derived versus recombinant factor VIII concentrates for the treatment of haemophilia A: plasma-derived is better.
    Mannucci PM
    Blood Transfus; 2010 Oct; 8(4):288-91. PubMed ID: 20967171
    [No Abstract]   [Full Text] [Related]  

  • 15. Recombinant factor VIII concentrate. The MSAC, Canadian Hemophilia Society. Canadian Hemophilia Clinic Directors Group.
    Walker I; Poon MC
    Lancet; 1992 Jan; 339(8784):61-2. PubMed ID: 1345984
    [No Abstract]   [Full Text] [Related]  

  • 16. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A.
    Hsu HC; Chen YF; Ho CH
    Zhonghua Yi Xue Za Zhi (Taipei); 1999 Jul; 62(7):450-4. PubMed ID: 10418180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant factor VIII may not abolish risk of new variant CJD from factor VIII.
    Betts JP
    BMJ; 1998 May; 316(7141):1385. PubMed ID: 9564003
    [No Abstract]   [Full Text] [Related]  

  • 18. Creutzfeldt-Jakob disease and haemophilia: prospect at the new millennium.
    Liras A
    Haemophilia; 2000 Nov; 6(6):716-8. PubMed ID: 11122406
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment for haemophilia by postcode.
    Ludlam CA; Hay CR; Dolan G
    BMJ; 1997 Mar; 314(7082):749. PubMed ID: 9116559
    [No Abstract]   [Full Text] [Related]  

  • 20. After the SIPPET study: Position paper of the CoMETH, the French society of haemophilia.
    Lebreton A; Castet S; Falaise C; Rugeri L; Schved JF; Wibaut B
    Haemophilia; 2018 Mar; 24(2):e55-e57. PubMed ID: 29316084
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.